Boxer Capital Management LLC Buys New Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Boxer Capital Management LLC bought a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,027,678 shares of the company's stock, valued at approximately $28,185,000. Tyra Biosciences comprises 2.4% of Boxer Capital Management LLC's investment portfolio, making the stock its 10th biggest position. Boxer Capital Management LLC owned 4.01% of Tyra Biosciences at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of TYRA. KLP Kapitalforvaltning AS acquired a new position in Tyra Biosciences in the 4th quarter valued at $31,000. US Bancorp DE acquired a new position in shares of Tyra Biosciences during the fourth quarter worth about $50,000. Aquatic Capital Management LLC purchased a new position in Tyra Biosciences during the fourth quarter worth about $64,000. Wells Fargo & Company MN lifted its position in Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock valued at $132,000 after purchasing an additional 3,236 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in Tyra Biosciences by 130,587.5% in the 4th quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company's stock valued at $145,000 after purchasing an additional 10,447 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TYRA. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Tyra Biosciences in a report on Monday, March 31st. UBS Group started coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They set a "buy" rating and a $28.00 price target on the stock. Finally, Wedbush reiterated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Price Performance

Tyra Biosciences stock traded down $0.47 during mid-day trading on Wednesday, hitting $9.53. 282,519 shares of the company were exchanged, compared to its average volume of 256,376. The company has a market capitalization of $505.95 million, a P/E ratio of -5.95 and a beta of 1.17. The business's 50 day simple moving average is $9.73 and its two-hundred day simple moving average is $13.59. Tyra Biosciences, Inc. has a 12-month low of $6.42 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.05. Equities research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.